The effect of cancer stage and treatment modality on quality of life in oropharyngeal cancer
Abstract
Objectives/Hypothesis To examine changes in health-related quality of life among oropharyngeal cancer patients by stages and across treatment types among advanced cancer patients. Study Design Individual prospective cohort study. Methods All newly diagnosed patients with oropharyngeal cancer treated with curative intent were routinely assessed. The European Organization for Research and Treatment of Cancer (EORTC) both the Main Module quality-of-life questionnaire (QLQ-C30) and the Head and Neck Cancer (HNC) Module (QLQ-H&N35) were administered at diagnosis and 3, 6, and 12 months thereafter. Complete case analysis was used following assessment of missing data. The proportion of patients with clinically significant deterioration (changes of ≥10 points) from baseline were calculated for each follow-up time point and compared by stage (I/II vs. III/IV) and then treatment type (chemotherapy and radiotherapy [CRT] vs. surgery and postoperative radiotherapy [S&PORT]). Results Deterioration in most domains was most frequent for stage III/IV patients at 3 months (both modules), whereas stage I/II patients experienced this at 6 months (QLQ-C30) and 12 months (H&N35). Among stage III/IV patients, this happened at all time points for S&PORT patients (QLQ-C30) versus 12 months for CRT patients (H&N35). The number of patients reporting deterioration was lower for most domains at 12 months compared to earlier periods, although dry mouth remained a problem for most patients (60%-85% across treatment/stage groups). Conclusions Our preliminary findings suggest that general and disease-specific deterioration is of most concern for stage I/II patients at 6 and 12 months and at 3 months for advanced cancer patients. For stage III/IV patients receiving S&PORT, general deterioration remains a problem after diagnosis, whereas for CRT patients, disease-specific deterioration is of most concern at 12 months. Level of Evidence 4. Laryngoscope, 124:151-158, 2014
Keywords
chemoradiation, Head and neck cancer, oropharyngeal cancer, quality of life, surgery and postoperative radiotherapy, cetuximab, cisplatin, tirapazamine, advanced cancer, cancer chemotherapy, cancer patient, cancer radiotherapy, cancer staging, cancer surgery, cancer survival, chemoradiotherapy, cohort analysis, conference paper, constipation, coughing, deterioration, diarrhea, dyspnea, fatigue, female, follow up, head and neck cancer module, human, insomnia, intensity modulated radiation therapy, loss of appetite, major clinical study, male, multimodality cancer therapy, named inventories, questionnaires and rating scales, nausea and vomiting, oropharynx cancer, pain, percutaneous endoscopic gastrostomy, postoperative care, priority journal, prospective study, quality of life, Quality of Life Questionnaire, soft palate, tongue cancer, tonsil cancer, xerostomia, article, cancer staging, head and neck cancer, oropharynx cancer, oropharynx tumor, pathology, surgery and postoperative radiotherapy, chemoradiation, Head and neck cancer, oropharyngeal cancer, quality of life, surgery and postoperative radiotherapy, Female, Humans, Male, Neoplasm Staging, Oropharyngeal Neoplasms, Prospective Studies, Quality of Life
Document Type
Conference Proceeding
Date of Publication
1-1-2014
Faculty
Faculty of Health, Engineering and Science
Publisher
Wiley
School
School of Nursing and Midwifery
RAS ID
19355
Copyright
free_to_read
Comments
Oates J., Davies S., Roydhouse J.K., Fethney J., White K. (2014). The effect of cancer stage and treatment modality on quality of life in oropharyngeal cancer. Laryngoscope. (pp. 151-158). John Wiley and Sons Inc.. Available here